FogPharma
FogPharma is a clinical-stage biopharmaceutical company developing Helicon™ peptide therapies to target intracellular disease drivers previously inaccessible to traditional medicines. Its lead candidate, FOG-001, is a β-catenin inhibitor in Phase 1/2 trials for solid tumors, addressing a significant unmet need in oncology. The company leverages AI and computational physics in its drug discovery process.
Buy Funded Startups lists
Funding Round: Series E
Funding Amount: $145M
Date: 01-Mar-2024
Investors: Nextech Invest, RA Capital Management, Rock Springs Capital, General Catalyst, Marshall Wace, Samsara Biocapital, Foresite Capital, Symbiosis, Catalio Capital Management, Sixty Degree Capital, Alex Gorsky, ARCH Venture Partners, Fidelity Management & Research Company, GV, Cormorant Asset Management, funds and accounts advised by T. Rowe Price Associates, Inc., Farallon Capital Management, venBio Partners, Invus, Milky Way Investments
Markets: Biotechnology, Pharmaceuticals, Oncology, Health Care, Life Science, Precision Medicine
HQ: Cambridge, Massachusetts, United States
Founded: 2015
Website: https://www.fogpharma.com
LinkedIn: https://www.linkedin.com/company/fog-pharmaceuticals/
Crunchbase: https://www.crunchbase.com/organization/fog-pharmaceuticals
Leave a Comment
Comments
No comments yet.